<DOC>
<DOCNO>en.15.187.481.2007.5.30</DOCNO>
<TITLE> UK's NICE endorses quit-smoking drug from Pfizer </TITLE>
<TEXT>
 LONDON, May 30 (bdnews24.com/Reuters) - Britain's cost-effectiveness watchdog NICE has recommended Pfizer Inc's smoking cessation drug Champix for use by the state-funded National Health Service, the US drugmaker said on Wednesday. In its final appraisal determination, the National Institute for Health and Clinical Excellence (NICE) concluded the drug was better than nicotine replacement therapy and GlaxoSmithKline Plc's Zyban pill in helping smokers quit. Champix, the first new prescription product for smoking cessation, targets the specific receptor to which nicotine binds, thereby reducing the severity of the smoker's urge to smoke. The medicine is sold as Chantix in the United States. It was approved as safe and effective by European and US regulators last year
</TEXT>
</DOC>
